Rheos Capital Works’s BioNTech BNTX Stock Holding History

Rheos Capital Works’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.6M	Buy	+125,000	New	+$11.8M	0.66%	60

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Rheos Capital Works's BNTX Position: Q2 2026 in Review

Rheos Capital Works opened a new position in BioNTech (BNTX) in Q2 2026: 125,000 shares worth $11.6M. The stake represents 0.66% of the portfolio and ranks #60 among its holdings.

281 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Rheos Capital Works held 125,000 shares of BioNTech worth $11.6M as of Q2 2026.
BioNTech was a new Rheos Capital Works position in Q2 2026.
BioNTech made up 0.66% of Rheos Capital Works's portfolio in Q2 2026, its #60 holding.
281 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Rheos Capital Works's 13F filing for Q2 2026, filed 7 Aug 2026.